Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
4AB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€147.60 - €204.45
Previous CloseN/A
Volume1.25K
Average Volume (3M)429.00
Market Cap
$316.39B
Enterprise Value€392.79B
Total Cash (Recent Filing)$5.18B
Total Debt (Recent Filing)$69.89B
Price to Earnings (P/E)92.6
Beta0.32
Next Earnings
Oct 24, 2025EPS Estimate
2.79Last Dividend Ex-Date
Jul 15, 2025Dividend Yield3.31%
Share Statistics
EPS (TTM)2.54
Shares Outstanding1,766,558,200
10 Day Avg. Volume258
30 Day Avg. Volume429
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue6.85
Enterprise Value/Gross Profit9.69
Enterprise Value/Ebitda26.50
Forecast
1Y Price Target
$190.13Price Target Upside6.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Acquisition And Pipeline ExpansionThe acquisition of Bretisilocin is a solid addition to AbbVie's Neuro pipeline and fits well with its fast-growing Neuro franchise, which is in the large Major Depressive Disorder category.
Earnings And Financial PerformanceAbbVie reported a big Q2 beat - with revenues at $15.4B, and EPS of $2.97, both exceeding consensus estimates.
Revenue GuidanceA second straight raise to revenue guidance, representing an $800mn increase to the prior guide.
Bears Say
Product PerformanceMore rapid deterioration of Humira counterbalances the upsides in R&S and Vyalev.
Sales DeclineSales in Aesthetics declined again sequentially due to economic challenges and low consumer sentiment.
AbbVie News
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €147.60 and its highest was €204.45 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $316.39B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 24, 2025 which is in 56 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 31, 2025. The company reported €2.539 earnings per share for the quarter, beating the consensus estimate of €2.462 by €0.077.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.412 which represents an annual dividend yield of 3.31%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 2.79.
How many shares outstanding does AbbVie have?
AbbVie has 1,766,558,200 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.539 in its last earnings report, beating expectations of €2.462. Following the earnings report the stock price went up 2.286%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in DE:4AB
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$190.13 (6.10% Upside)
$190.13 (6.10% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.30%
12-Months-Change
Fundamentals
Return on Equity
112.90%
Trailing 12-Months
Asset Growth
-3.35%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
4AB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with significant achievements in revenue growth, pipeline advancement, and strategic acquisitions. However, challenges remain in specific segments such as HUMIRA sales and the aesthetics market.View all DE:4AB earnings summaries4AB Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
4AB Stock 12 Month Forecast
Average Price Target
€190.13
▲(6.10% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
20.51%
Mutual Funds
13.51% Other Institutional Investors
43.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---